Abstract
Large-scale genetic screens are becoming increasingly used as powerful tools to query the genome to identify therapeutic targets in cancer. The advent of the CRISPR technology has revolutionized the effectiveness of these screens and has made it possible to carry out loss-of-function screens to identify cancer-specific genetic interactions. Such loss-of-function screens can be performed in silico, in vitro, and in vivo, depending on the scale of the screen, as well as research questions to be answered. Performing screens in vivo has its challenges but also advantages, providing opportunities to study the tumor microenvironment and cancer immunity. In this chapter, we present a procedural framework and associated notes for conducting in vivo CRISPR knockout screens in cancer models to study cancer biology, anti-tumor immune responses, tumor microenvironment, and predicting treatment responses.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hart T, Brown KR, Sircoulomb F et al (2014) Measuring error rates in genomic perturbation screens: gold standards for human functional genomics. Mol Syst Biol 10:733
Castells-Roca L, Tejero E, RodrÃguez-Santiago B et al (2021) CRISPR screens in synthetic lethality and combinatorial therapies for cancer. Cancers (Basel) 13:1591
Wang T, Birsoy K, Hughes NW et al (2015) Identification and characterization of essential genes in the human genome. Science 350:1096–1101
Iorio F, Behan FM, Gonçalves E et al (2018) Unsupervised correction of gene-independent cell responses to CRISPR-Cas9 targeting. BMC Genomics 19:604
Wang W, Malyutina A, Pessia A et al (2019) Combined gene essentiality scoring improves the prediction of cancer dependency maps. EBioMedicine 50:67–80
Shalem O, Sanjana NE, Hartenian E et al (2014) Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343:84–87
Wang T, Wei JJ, Sabatini DM et al (2014) Genetic screens in human cells using the CRISPR-Cas9 system. Science 343:80–84
Zhou Y, Zhu S, Cai C et al (2014) High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells. Nature 509:487–491
Koike-Yusa H, Li Y, Tan E-P et al (2014) Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nat Biotechnol 32:267–273
Chafe SC, Vizeacoumar FS, Venkateswaran G et al (2021) Genome-wide synthetic lethal screen unveils novel CAIX-NFS1/xCT axis as a targetable vulnerability in hypoxic solid tumors. Sci Adv 7:eabj0364
Cunningham CE, MacAuley MJ, Yadav G et al (2019) Targeting the CINful genome: strategies to overcome tumor heterogeneity. Prog Biophys Mol Biol 147:77–91
Parameswaran S, Kundapur D, Vizeacoumar FS et al (2019) A road map to personalizing targeted cancer therapies using synthetic lethality. Trends Cancer 5:11–29
Paul JM, Templeton SD, Baharani A et al (2014) Building high-resolution synthetic lethal networks: a ‘Google map’ of the cancer cell. Trends Mol Med 20:704–715
Kryukov GV, Wilson FH, Ruth JR et al (2016) MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science 351:1214–1218
Kirzinger MWB, Vizeacoumar FS, Haave B et al (2019) Humanized yeast genetic interaction mapping predicts synthetic lethal interactions of FBXW7 in breast cancer. BMC Med Genomics 12:112
McManus KJ, Barrett IJ, Nouhi Y et al (2009) Specific synthetic lethal killing of RAD54B-deficient human colorectal cancer cells by FEN1 silencing. Proc Natl Acad Sci U S A 106:3276–3281
MacAuley MJ, Abuhussein O, Vizeacoumar FS (2021) Identification of synthetic lethal interactions using high-throughput, arrayed CRISPR/Cas9-based platforms. Methods Mol Biol 2381:135–149
Liu D, Zhao X, Tang A et al (1874) CRISPR screen in mechanism and target discovery for cancer immunotherapy. Biochim Biophys Acta Rev Cancer 2020:188378
Manguso RT, Pope HW, Zimmer MD et al (2017) In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature 547:413–418
Schaefer C, Mallela N, Seggewiß J et al (2018) Target discovery screens using pooled shRNA libraries and next-generation sequencing: a model workflow and analytical algorithm. PLoS One 13:e0191570
Dahn ML, Marcato P (2021) In vivo genome-wide pooled RNAi screens in cancer cells to identify determinants of chemotherapy/drug response. In: Vizeacoumar FJ, Freywald A (eds) Mapping genetic interactions. Springer, New York, pp 189–200
Giuliano CJ, Lin A, Girish V et al (2019) Generating single cell–derived knockout clones in mammalian cells with CRISPR/Cas9. Curr Protoc Mol Biol 128:e100
Colic M, Hart T (2021) Common computational tools for analyzing CRISPR screens. Emerg Top Life Sci 5:779–788
Li W, Xu H, Xiao T et al (2014) MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. Genome Biol 15:554
Acknowledgments
This work was supported by operating grants from Saskatchewan Cancer Agency and Canadian Foundation for Innovation (CFI-33364) to F.J.V. and Be Like Bruce Foundation and College of Medicine funding, University of Saskatchewan to F.J.V and A.F. Figures were drawn using an image bundle purchased from Motifolio.
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Maranda, V., Zhang, Y., Vizeacoumar, F.S., Freywald, A., Vizeacoumar, F.J. (2023). A CRISPR Platform for Targeted In Vivo Screens. In: Ursini-Siegel, J. (eds) The Tumor Microenvironment. Methods in Molecular Biology, vol 2614. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-2914-7_24
Download citation
DOI: https://doi.org/10.1007/978-1-0716-2914-7_24
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-2913-0
Online ISBN: 978-1-0716-2914-7
eBook Packages: Springer Protocols